

LA JOLLA CANCER RESEARCH FOUNDATION
ANIMAL USAGE FORM

AUF 1413

PLEASE TYPE OR PRINT

1. PRINCIPAL INVESTIGATOR
WAYNE A. BORDER, M.D. OFFICE PHONE 226 HOME/EMERGENCY PHONE (714) 770-4602

2. OTHER INVESTIGATOR
LUCIA LANGUINO, Ph.D. 230 539-0609

3. SENIOR TECHNICIAN

4. PROJECT TITLE
ANTI-HUMAN TGF β CYCLIZED PEPTIDE

5. GRANT NUMBER, IF ANY 250200 NEW ☒ RENEWAL ☐ PILOT ☐ PROJECT NUMBER

6. START DATE END DATE MICE RATS RABBITS 2 GPs OTHER (SPECIFY)

7. PROJECT GOAL (SEE INSTRUCTIONS)
To produce quantities of anti-human TGF β cyclized peptide for use in kidney disease research.

8. RATIONALE (SEE INSTRUCTIONS)
Rabbits produce high quality antiserum which can be used for identification of human TGF β in tissue samples and in vitro assays to study progression of kidney injury.

9. DESCRIBE USE OF ANIMALS (SEE INSTRUCTIONS)
All injections/bleedings to be performed by animal care facility personnel.
1. Pre-bleeding 20 ml from ear vein.
2. Inject 500 μ g TGF β cyclized purified peptide (0.5 ml antigen in PBS + 0.5 ml FCA) subcutaneously in 2 sites.
3. After one month, boost with 125 μ g antigen (0.25 ml antigen in PBS + 0.25 ml incomplete adjuvant) subcutaneously, 2 sites.
4. After 10 days, bleed 50 ml from alternating ear veins 3 times.
5. Repeat steps 3-4 at 4-6 week intervals.

ALL ANIMAL RESEARCH COMMITTEE
POLICY: ALL ANIMAL RESEARCH
PERSONNEL MUST BE TRAINED
AND APPROVED BY THE COMMITTEE
INJECTION OF VIT D $_3$ WHICH
AND/OR PARACETAMOL
MAY BE USED IN THIS
RESEARCH PROTOCOL

10. PAIN LEVEL A ☒ B ☐ C ☐ (IF B OR C READ INSTRUCTIONS. PROVIDE DESCRIPTION OR JUSTIFICATION HERE)

CONFIDENTIAL

11. EUTHANASIA (SEE INSTRUCTIONS)
DURING PROJECT ☐ METHOD OR TECHNIQUE CO. ☐ CERV. DISLOC. ☐ RETAIN CARCASSES? YES ☐
END OF PROJECT ☒ O.D. ☒ OTHER (SPECIFY) ☐ FOR PI NO ☒

12. SIGNATURES
PI WABorder DATE 1/1
AF MGR DATE

U2 05334